Perioperative Nivolumab in Resectable Lung Cancer. Reply

MeSH terms

• Antineoplastic Agents, Immunological / administration & dosage
• Antineoplastic Agents, Immunological / adverse effects
• Carcinoma, Non-Small-Cell Lung* / drug therapy
• Carcinoma, Non-Small-Cell Lung* / mortality
• Carcinoma, Non-Small-Cell Lung* / surgery
• Chemotherapy, Adjuvant / adverse effects
• Chemotherapy, Adjuvant / methods
• Clinical Trials, Phase III as Topic
• Hospital Mortality
• Humans
• Immune Checkpoint Inhibitors / administration & dosage
• Immune Checkpoint Inhibitors / adverse effects
• Lung Neoplasms* / drug therapy
• Lung Neoplasms* / mortality
• Lung Neoplasms* / surgery
• Neoadjuvant Therapy / adverse effects
• Neoadjuvant Therapy / methods
• Nivolumab* / administration & dosage
• Nivolumab* / adverse effects
• Perioperative Care / adverse effects
• Perioperative Care / methods
• Pneumonectomy / methods
• Pneumonectomy / statistics & numerical data
• Randomized Controlled Trials as Topic
• Treatment Outcome